1. Scrip
  2. >>Therapy Areas

Enhertu Poised To Rewrite The Standard Of Care After ESMO

 
• By Jessica Merrill

AstraZeneca/Daiichi Sankyo's Enhertu is poised to become the new standard of care for second-line HER2-positive breast cancer after handedly beating Roche's Kadcyla on PFS.

high jump
AZ/Daiichi's Enhertu raised the bar in advanced HER2-positive breast cancer • Source: Alamy

AstraZeneca PLC/Daiichi Sankyo Co., Ltd.'s Enhertu (trastuzumab deruxtecan) was one of the standout drugs at the European Society for Medical Oncology (ESMO) meeting, with head-to-head data from DESTINY-Breast03 presented on 18 September showing an overwhelming benefit on progression-free survival (PFS) versus Roche Holding AG's Kadcyla (trastuzumab emtansine) in second-line, HER2-positive breast cancer.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By Kevin Grogan

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

More from Therapy Areas

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.